Management volunteers specific, checkable numbers about the near future — quantified forward commitments it could visibl
The model's full reasoning — Q1 2018 call → NOWe need to determine if management volunteers specific, checkable numbers or dates about what the company's own business will do in the near term, presented as commitments describing a step-up from current level, grounded in things management says it can already see. The transcript includes forward guidance: revenue growth 15-16% for 2018, EPS ranges, etc. But that's routine financial guidance. The question asks about specific operational commitments like production levels, shipments, launches, etc. Management mentions: "we continue to expect 330 to 350 NovaSeq shipments this year" - that's a specific number for the year, but is it a step-up? It's a continuation of prior guidance. Also, they mention "we are now expecting 2018 revenue in the range 3.17 billion and 3.19 billion" - that's financial guidance. They also mention "we expect to scale shipments midyear" for iSeq, but no specific number. They mention "approaching 100 orders" for iSeq, but that's current. They mention "we expect continued growth in our sequencing consumable and system businesses" - qualitative. They mention "we are planning some incremental R&D and commercial projects" - not specific. They mention "we expect full-year non-GAAP operating expenses to be flat to slightly up" - that's financial. They mention "we expect gross margins to decline about a 100 basis points sequentially" - that's financial. They mention "we expect share count for the full year to be approximately a 148 million" - that's financial. They mention "we expect modest sequential growth" for Q2 - that's qualitative. They mention "we expect continued growth in our sequencing consumable and system businesses" - qualitative. They mention "we expect to see continued reductions in price" - that's not a commitment. They mention "we expect to complete sequencing all 100,000 genomes this year" for Genomics England - but that's a customer's program, not Illumina's own business? Actually, it's a program they enable, but it's not their own commitment. They mention "we expect to see the data come back from that study" for Harvard Pilgrim - that's a study, not a business commitment. They mention "we expect to see more of that happen" - qualitative. The only specific numbers are the NovaSeq shipments (330-350) and revenue guidance.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| RCEL | AVITA Medical, Inc. | Q1 2024 | 2024-05-14 | F |
| ERO | Ero Copper Corp. | Q1 2024 | 2024-05-10 | A |
| LINC | Lincoln Educational Services Corporation | Q1 2024 | 2024-05-06 | B+ |
| WEC | WEC Energy Group, Inc. | Q1 2024 | 2024-05-01 | A |
| PDS | Precision Drilling Corporation | Q1 2024 | 2024-04-25 | B |
| ASM | Avino Silver & Gold Mines Ltd. | Q4 2023 | 2024-03-21 | C+ |
| KOPN | Kopin Corporation | Q4 2023 | 2024-03-14 | C+ |
| LILA | Liberty Latin America Ltd. | Q4 2023 | 2024-02-23 | C |
| GPRE | Green Plains Inc. | Q4 2023 | 2024-02-07 | F |
| BRBR | BellRing Brands, Inc. | Q4 2023 | 2023-11-21 | B+ |
| CMG | Chipotle Mexican Grill, Inc. | Q3 2023 | 2023-10-27 | B+ |
| DXLG | Destination XL Group, Inc. | Q2 2023 | 2023-08-24 | D |
| IMAX | IMAX Corporation | Q2 2023 | 2023-07-26 | B+ |
| GGR | Gogoro Inc. | Q1 2023 | 2023-05-11 | D |
| CDE | Coeur Mining, Inc. | Q1 2023 | 2023-05-11 | C+ |
| SLDP | Solid Power, Inc. | Q1 2023 | 2023-05-08 | C+ |
| TACT | TransAct Technologies Incorporated | Q4 2022 | 2023-03-08 | A |
| DKS | DICK'S Sporting Goods, Inc. | Q4 2022 | 2023-03-07 | B |
| ADPT | Adaptive Biotechnologies Corporation | Q4 2022 | 2023-02-14 | C+ |
| CEIX | CONSOL Energy Inc. | Q4 2022 | 2023-02-07 | B |
| SOL | ReneSola Ltd | Q3 2022 | 2022-12-01 | C+ |
| CIG | Companhia Energética de Minas Gerais | Q3 2022 | 2022-11-16 | C+ |
| CHUY | Chuy's Holdings, Inc. | Q3 2022 | 2022-11-05 | C+ |
| TWO | Two Harbors Investment Corp. | Q2 2022 | 2022-08-04 | C+ |
| OGI | OrganiGram Holdings Inc. | Q3 2022 | 2022-07-14 | B+ |
| SQM | Sociedad Química y Minera de Chile S.A. | Q1 2022 | 2022-05-19 | C+ |
| BFIN | BankFinancial Corporation | Q1 2022 | 2022-05-06 | A |
| FAT | FAT Brands Inc. | Q4 2021 | 2022-03-21 | F |
| SLQT | SelectQuote, Inc. | Q2 2022 | 2022-02-07 | F |
| HNRG | Hallador Energy Company | Q3 2021 | 2021-11-09 | C+ |
| FFWM | First Foundation Inc. | Q3 2021 | 2021-10-26 | B |
| OWL | Blue Owl Capital Inc. | Q2 2021 | 2021-08-10 | B+ |
| PRPO | Precipio, Inc. | Q3 2018 | 2018-11-19 | D |
| WES | Western Midstream Partners, LP | Q3 2018 | 2018-10-31 | D |
| MAS | Masco Corporation | Q3 2018 | 2018-10-30 | C |
| CUBI | Customers Bancorp, Inc. | Q3 2018 | 2018-10-26 | C+ |
| T | AT&T Inc. | Q3 2018 | 2018-10-24 | C+ |
| IRT | Independence Realty Trust, Inc. | Q2 2018 | 2018-08-02 | B |
| ASND | Ascendis Pharma A/S | Q1 2018 | 2018-05-30 | C+ |
| CLMT | Calumet Specialty Products Partners, L.P | Q1 2018 | 2018-05-16 | C+ |
| ITCI | Intra-Cellular Therapies, Inc. | Q4 2017 | 2018-03-01 | D |
| CPK | Chesapeake Utilities Corporation | Q3 2017 | 2017-11-10 | A |
| BCE | BCE Inc. | Q2 2017 | 2017-08-05 | B+ |
| GPOR | Gulfport Energy Corporation | Q4 2016 | 2017-02-14 | A |
| PSX | Phillips 66 | Q4 2016 | 2017-02-03 | C+ |
| LBTYK | Liberty Global's | Q1 2016 | 2016-05-10 | C+ |
| GOGO | Gogo Inc. | Q1 2016 | 2016-05-06 | C+ |
TWO · Q2 2022 → YESThe question is about whether management volunteers specific, checkable numbers or dates about the company's own business in the near term that show a step-up, grounded in things they can already see....YES The transcript shows management volunteering a concrete, checkable commitment on the RoundPoint acquisition: they expect incremental annual pre-tax earnings of approximately $20 million once the portfolio is fully transferred (with Mary Riskey later confirming $0.45 per share after-tax accretion). They also state they will begin transitioning loans to Round Point as a subservicer later this year and expect the acquisition to close in 2023. These are presented as owned expectations tied to the in-house servicing model they are already executing, describing a clear step-up in earnings and operational activity above the current subservicing level.
CUBI · Q3 2018 → YESThe question is about whether management volunteers specific, checkable numbers or dates about the company's own business in the near term, presenting them as commitments for a step-up from current le...YES Management volunteers concrete, checkable commitments for the near term (next 12–18 months) that describe a clear step-up from current levels and are grounded in things already in motion or in hand. Examples include: - NIM target of 2.75% within 12–18 months, explicitly tied to 3–4 rate hikes and the $495 million securities sale plus $500 million borrowings repayment already executed. - $600 million core-franchise deposit growth + $500–600 million CB digital + $500 million BankMobile white-label deposits next year, building on the $1.
ADPT · Q4 2022 → YESThe question is: Does management volunteer specific, checkable numbers or dates about what the company's own business will do in the near term — quantified forward commitments concrete enough that inv...YES Management volunteers concrete, checkable commitments for 2023 that describe a clear step-up: full-year revenue of $205–215 million (versus $185.3 million in 2022), clonoSEQ test volumes growing more than 50% from the current base, MRD pharma milestones in the mid to high-single-digit millions, community business reaching 20% of total revenue (from 15% currently), and 2023 OpEx (including cost of revenue) slightly below the 2022 level of $385.5 million, with average quarterly cash burn of $40 million.